ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
24 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
905
|
272K
|
24
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
9 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
905
|
272K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
33 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
905
|
272K
|
33
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
8 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
905
|
272K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
16 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
905
|
272K
|
16
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
61 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
905
|
272K
|
61
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
7 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
905
|
272K
|
7
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Mason14
|
22K |
7.8M |
2 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
22K
|
7.8M
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
58 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
905
|
272K
|
58
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
28 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
905
|
272K
|
28
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
55 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
905
|
272K
|
55
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
50 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
905
|
272K
|
50
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
13 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
146
|
45K
|
13
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
24 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
146
|
45K
|
24
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
36 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
146
|
45K
|
36
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
62 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
146
|
45K
|
62
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
73 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
146
|
45K
|
73
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
44 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
146
|
45K
|
44
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
18 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
146
|
45K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
45 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
45K
|
45
|
|
ASX - By Stock
|
RAC |
Re:
RAC - Crystal ball gazing
|
|
Mason14
|
38 |
8.1K |
6 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
38
|
8.1K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
RAC - Crystal ball gazing
|
|
Mason14
|
38 |
8.1K |
43 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
38
|
8.1K
|
43
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
50 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
45K
|
50
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
50 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
45K
|
50
|
|
ASX - By Stock
|
RAC |
Re:
CPACS: Research, Results, Market Comparisons, and Valuations
|
|
Mason14
|
295 |
87K |
55 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
295
|
87K
|
55
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Mason14
|
146 |
45K |
76 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
146
|
45K
|
76
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
71 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
905
|
272K
|
71
|
|
ASX - By Stock
|
RAC |
CPACS: Research, Results, Market Comparisons, and Valuations
|
|
Mason14
|
295 |
87K |
130 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
295
|
87K
|
130
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Mason14
|
905 |
272K |
15 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
905
|
272K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
52 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
391
|
83K
|
52
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
44 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
83K
|
44
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
52 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
83K
|
52
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
40 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
83K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
43 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
83K
|
43
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
43 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
83K
|
43
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
35 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
83K
|
35
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
61 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
83K
|
61
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
37 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
83K
|
37
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
39 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
83K
|
39
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Mason14
|
11K |
4.0M |
106 |
10/07/24 |
10/07/24 |
General
|
11K
|
4.0M
|
106
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
23 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
83K
|
23
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
66 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
83K
|
66
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
35 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
83K
|
35
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Mason14
|
11K |
4.0M |
73 |
09/07/24 |
09/07/24 |
General
|
11K
|
4.0M
|
73
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Mason14
|
11K |
4.0M |
91 |
09/07/24 |
09/07/24 |
General
|
11K
|
4.0M
|
91
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
66 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
83K
|
66
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Mason14
|
391 |
83K |
9 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
83K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mason14
|
15K |
7.4M |
10 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
15K
|
7.4M
|
10
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mason14
|
15K |
7.4M |
2 |
06/07/24 |
06/07/24 |
ASX - By Stock
|
15K
|
7.4M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial
|
|
Mason14
|
71 |
27K |
10 |
06/07/24 |
06/07/24 |
ASX - By Stock
|
71
|
27K
|
10
|
|